ChemicalBook Product Catalog Biochemical Engineering Inhibitors KY19382

KY19382

Product NameKY19382
CAS2226664-93-1
MFC17H11Cl2N3O2
MW360.19
EINECS206-696-4
MOL File2226664-93-1.mol

Chemical Properties

Density	1.58±0.1 g/cm3(Predicted)
solubility	DMSO: Soluble
pka	8.80±0.20(Predicted)
form	Solid
color	Brown to reddish brown
InChI	InChI=1S/C17H11Cl2N3O2/c1-24-22-15-8-4-2-3-5-12(8)20-16(15)14-9-6-10(18)11(19)7-13(9)21-17(14)23/h2-7,20H,1H3,(H,21,23)
InChIKey	PROTUMHDKVZVBW-UHFFFAOYSA-N
SMILES	N1C2=C(C=C(Cl)C(Cl)=C2)C(=C2C(=NOC)C3=C(N2)C=CC=C3)C1=O

Usage And Synthesis

Description

KY19334 is a small molecule that activates the Wnt/β-catenin pathway by inhibiting the CXXC5–Dvl interaction and accelerates wound healing in diabetic mice. By restoring the suppressed Wnt/β-catenin signaling and thereby inducing the expression of its target genes, KY19334 enhances the wound-healing capacity of diabetic mice. Furthermore, KY19334 induces angiogenesis in mice with hindlimb ischemia.

Uses

KY 19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β.

in vivo

KY19382 (0.1 mg/kg; i.p. once daily for 2 weeks) delays growth plate senescence in older mice and promotes growth plate maturation in rapidly growing young mice^[1].
KY19382 (0.1 mg/kg; i.p. once daily for 10 weeks) significantly increases the length of tibiae in mice^[1].
KY19382 (5 mg/kg; i.p.) displays a relatively favorable bioavailability (F=16.74%), showing half-life of 16.20 h and an exposure level of 6,555.79 ngh/ml^[1].
KY19382 (A3051) (25 mg/kg; p.o. once daily for 16 weeks) shows reduction in adipocyte size and anti-inflammatory effects^[2].
A3051 (25 mg/kg; p.o. once daily for 5 days) reduces fasting glucose in mice^[2].
A3051 (25 mg/kg; p.o. once daily for 3 weeks) reduces the hepatosteatosis in mice^[2].

Animal Model:	C57BL/6 male mice (7-weeks-old or 3-weeks-old)^[1]
Dosage:	0.1 mg/kg
Administration:	I.p. once daily for 2 weeks
Result:	Increased nuclear β-catenin in the growth plate chondrocytes dramatically. Elevated the height of each growth plate zone and BrdU-positive cells. Did not affect the cartilage resorption of rapidly growing young mice.

Animal Model:	SD male rats^[1]
Dosage:	1 mg/kg for i.v. and 5 mg/kg for i.p. (Pharmacokinetic Analysis)
Administration:	I.v. and i.p. administration
Result:	I.v.: t_1/2=3.33 h; AUC=7832.81 ngh/mL; CL=0.12 L/h/kg. I.p.: t_1/2=16.20 h; F=16.74%; C_max=463.37 ng/mL.

IC 50

CXXC5-DVL: 19 nM (IC₅₀); GSK3β: 10 nM (IC₅₀)

References

[1] SEHEE CHOI. CXXC5 mediates growth plate senescence and is a target for enhancement of longitudinal bone growth.[J]. Life Science Alliance, 2019. DOI: 10.26508/lsa.201800254
[2] Yoon, Minguen, et al. “KY19382 Accelerates Cutaneous Wound Healing via Activation of the Wnt/β-Catenin Signaling Pathway.” International Journal of Molecular Sciences, 24 14, 2023, https://doi.org/10.3390/ijms241411742.
[3] Ryu, Yeong Chan, et al. “KY19382, a Novel Activator of Wnt/β-Catenin Signalling, Promotes Hair Regrowth and Hair Follicle Neogenesis.” British Journal of Pharmacology, 178 12, 2021, pp. 2533–46, https://doi.org/10.1111/bph.15438.
[4] Lee, Soung-Hoon, et al. “Novel Small Molecules Downregulate CDK1 Expression and Inhibit Wnt/β-Catenin Signaling in Cutaneous Squamous Cell Carcinoma by Targeting Its Distinct Tumor-Specific Cellular Landscape.” Experimental and Molecular Medicine, 57 9, 2025, pp. 1996–2009, https://doi.org/10.1038/s12276-025-01532-y.

KY19382 Supplier

KY19382 manufacturers

Related Product Information

Send Inquriy